이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

중등도에서 중증 화농땀샘염 성인 환자의 secukinumAb 치료 패턴에 대한 실제 인구 데이터를 수집하기 위한 장기 관찰, 전향적, 다기관 연구. (ANIMA)

2026년 11월 13일 업데이트: Novartis Pharmaceuticals

중등도에서 중증 화농땀샘염(HS) 성인 환자의 secukinumAb 치료 패턴에 대한 실제 인구 데이터를 수집하기 위한 장기 관찰, 전향적, 다기관 연구(ANIMA)

The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and decision influencing factors for flexible dosing in a real-world population over 2 years.

연구 개요

상태

모집하지 않고 적극적으로

개입 / 치료

상세 설명

The study will collect data from patients during routine secukinumab treatment and will be representative of the real-world patient population eligible for secukinumab treatment in Germany.

In order to attain widespread representation of health care practices related to the use of secukinumab in the approved indication of moderate to severe HS, a broad spectrum of dermatology practices and clinics who are treating patients with HS across Germany will be included.

연구 유형

관찰

등록 (실제)

436

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Aachen, 독일, 52064
        • Novartis Investigative Site
      • Ahaus, 독일, 48683
        • Novartis Investigative Site
      • Annaberg-Buchholz, 독일, 09456
        • Novartis Investigative Site
      • Bad Steben, 독일, 95138
        • Novartis Investigative Site
      • Baden-Baden, 독일, 76530
        • Novartis Investigative Site
      • Berlin, 독일, 12159
        • Novartis Investigative Site
      • Berlin, 독일, 13595
        • Novartis Investigative Site
      • Bielefeld, 독일, 33647
        • Novartis Investigative Site
      • Bochum, 독일, 44791
        • Novartis Investigative Site
      • Bonn, 독일, 53105
        • Novartis Investigative Site
      • Brandenburg, 독일, 14776
        • Novartis Investigative Site
      • Bremen, 독일, 28359
        • Novartis Investigative Site
      • Buxtehude, 독일, 21614
        • Novartis Investigative Site
      • Bückeburg, 독일, 31675
        • Novartis Investigative Site
      • Chemnitz, 독일, 09117
        • Novartis Investigative Site
      • Chemnitz, 독일, 09113
        • Novartis Investigative Site
      • Cologne, 독일, 51065
        • Novartis Investigative Site
      • Delitzsch, 독일, 04509
        • Novartis Investigative Site
      • Dessau, 독일, 06847
        • Novartis Investigative Site
      • Dorsten, 독일, 46282
        • Novartis Investigative Site
      • Dortmund, 독일, 44137
        • Novartis Investigative Site
      • Dresden, 독일, 01309
        • Novartis Investigative Site
      • Düren, 독일, 52349
        • Novartis Investigative Site
      • Emsdetten, 독일, 48282
        • Novartis Investigative Site
      • Erlangen, 독일, 91054
        • Novartis Investigative Site
      • Falkenberg, 독일, 04895
        • Novartis Investigative Site
      • Falkensee, 독일, 14612
        • Novartis Investigative Site
      • Freising, 독일, 85354
        • Novartis Investigative Site
      • Geilenkirchen, 독일, 52511
        • Novartis Investigative Site
      • Gera, 독일, 07548
        • Novartis Investigative Site
      • Gernsbach, 독일, 76593
        • Novartis Investigative Site
      • Gladbeck, 독일, 45964
        • Novartis Investigative Site
      • Großenhain, 독일, 01558
        • Novartis Investigative Site
      • Hamburg, 독일, 20246
        • Novartis Investigative Site
      • Hamburg, 독일, 22143
        • Novartis Investigative Site
      • Hanover, 독일, 30159
        • Novartis Investigative Site
      • Haslach im Kinzigtal, 독일, 77716
        • Novartis Investigative Site
      • Hofgeismar, 독일, 34369
        • Novartis Investigative Site
      • Jena, 독일, 07743
        • Novartis Investigative Site
      • Jülich, 독일, 52428
        • Novartis Investigative Site
      • Karlsruhe, 독일, 76133
        • Novartis Investigative Site
      • Kempen, 독일, 47906
        • Novartis Investigative Site
      • Lübeck, 독일, 23538
        • Novartis Investigative Site
      • Magdeburg, 독일, 39120
        • Novartis Investigative Site
      • Magdeburg, 독일, 39104
        • Novartis Investigative Site
      • Mainz, 독일, 55116
        • Novartis Investigative Site
      • Marburg, 독일, 35043
        • Novartis Investigative Site
      • Minden, 독일, 32429
        • Novartis Investigative Site
      • Mönchengladbach, 독일, 41063
        • Novartis Investigative Site
      • Neu Wulmstorf, 독일, 21629
        • Novartis Investigative Site
      • Nuremberg, 독일, 90419
        • Novartis Investigative Site
      • Oberasbach, 독일, 90522
        • Novartis Investigative Site
      • Oelde, 독일, 59302
        • Novartis Investigative Site
      • Peitz, 독일, 03185
        • Novartis Investigative Site
      • Potsdam, 독일, 14469
        • Novartis Investigative Site
      • Remscheid, 독일, 42897
        • Novartis Investigative Site
      • Selters, 독일, 56242
        • Novartis Investigative Site
      • Simmern, 독일, 55469
        • Novartis Investigative Site
      • Soest, 독일, 59494
        • Novartis Investigative Site
      • Stolberg, 독일, 52222
        • Novartis Investigative Site
      • Unna, 독일, 59423
        • Novartis Investigative Site
      • Wittlich, 독일, 54316
        • Novartis Investigative Site
      • Wuppertal, 독일, 42103
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Freiburg im Breisgau, Baden-Wurttemberg, 독일, 79068
        • Novartis Investigative Site
      • Rheinstetten, Baden-Wurttemberg, 독일, 76287
        • Novartis Investigative Site
    • Bavaria
      • Haßfurt, Bavaria, 독일, 97437
        • Novartis Investigative Site
      • Kulmbach, Bavaria, 독일, 95326
        • Novartis Investigative Site
      • Lauf an der Pegnitz, Bavaria, 독일, 91207
        • Novartis Investigative Site
      • Nuremberg, Bavaria, 독일, 90402
        • Novartis Investigative Site
    • Brandenburg
      • Panketal, Brandenburg, 독일, 16341
        • Novartis Investigative Site
    • Free and Hanseatic City of Hamburg
      • Hamburg, Free and Hanseatic City of Hamburg, 독일, 22549
        • Novartis Investigative Site
    • Lower Saxony
      • Lingen, Lower Saxony, 독일, 49809
        • Novartis Investigative Site
    • Mecklenburg-Vorpommern
      • Bergen auf Rügen, Mecklenburg-Vorpommern, 독일, 18528
        • Novartis Investigative Site
      • Kröpelin, Mecklenburg-Vorpommern, 독일, 18236
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Krefeld, North Rhine-Westphalia, 독일, 47798
        • Novartis Investigative Site
    • Rhineland-Palatinate
      • Mainz, Rhineland-Palatinate, 독일, 55128
        • Novartis Investigative Site
    • Saxony
      • Dresden, Saxony, 독일, 01307
        • Novartis Investigative Site
      • Leipzig, Saxony, 독일, 04207
        • Novartis Investigative Site
      • Leipzig, Saxony, 독일, 04289
        • Novartis Investigative Site
    • Saxony-Anhalt
      • Wittenberg, Saxony-Anhalt, 독일, 06886
        • Novartis Investigative Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

patients, being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.

설명

Inclusion Criteria:

Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:

  1. Patients who provide written informed consent to participate in the study
  2. Male and female patients with ≥18 years of age
  3. Diagnosis of clinically unequivocal moderate to severe HS
  4. Patients for whom a therapy with secukinumab is medically indicated
  5. Documented decision for treatment with marketed secukinumab regardless of this noninterventional study
  6. Treatment with secukinumab according to the latest version of SmPC
  7. Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit

Exclusion Criteria:

Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients:

  1. Patients who have any contraindications, such as a history of or active inflammatory bowel disease (Crohn´s disease, ulcerative colitis), and are not eligible for treatment with secukinumab according to the SmPC
  2. Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation
  3. Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with secukinumab
  4. Previous exposure to IL-17 inhibitors
  5. For biologic-naïve patients, previous exposure to another biologic drug, such as anti-TNF-α inhibitors

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
secukinumab

Patients being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.

Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Proportion of patients receiving up-titration
기간: Up to 24 months

Proportion of patients receiving up-titration (q4w-to-q2w)

Up to 24 months
Proportion of patients receiving down-titration
기간: Up to 24 months

Proportion of patients receiving down-titration (q2w-to-q4w)

Up to 24 months
Time to up-titration and down-titration
기간: Up to 2 years

Time to up-titration and down-titration

Up to 2 years
Duration of q4w treatment with secukinumab after dose reduction
기간: Up to 2 years

Duration of q4w treatment with secukinumab after dose reduction

Up to 2 years
Proportion of patients who receive more than one up-and/or down titration
기간: Up to 24 months

Proportion of patients who receive more than one up-and/or down titration

Up to 24 months
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab
기간: Up to 2 years

Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab

Up to 2 years
Number and type of surgical interventions
기간: Up to 2 years

Number and type of surgical interventions

  • minor and major surgical excision;
  • inpatient, outpatient
Up to 2 years
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)
기간: Up to 24 months

The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity.

HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS

Up to 24 months
mean change of International Hidradenitis Suppurativa Severity Score System (IHS4)
기간: Up to 24 months

The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity.

HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS

Up to 24 months
Proportion of patients achieving a 5-point reduction of their Dermatology Life Quality Index (DLQI) questionnaire
기간: Up to 24 months

The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school.

Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.

Up to 24 months
Mean reduction of Abscesses and inflammatory nodules (AN) count
기간: Up to 24 months

Mean reduction of Abscesses and inflammatory nodules (AN) count

Up to 24 months
Proportion of patients achieving a 30% reduction of pain Numerical Rating scale 30 (NRS30)
기간: Up to 24 months

The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). To assess this, the patient should concentrate on the pain that his/her skin lesions generate. The Patient's Global Assessment of Skin Pain - NRS will be completed by the subject electronically via a web-based application or in paper form.

Up to 24 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Novartis Pharmaceuticals, Novartis Pharmaceuticals

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 8월 10일

기본 완료 (추정된)

2027년 3월 31일

연구 완료 (추정된)

2027년 3월 31일

연구 등록 날짜

최초 제출

2023년 6월 16일

QC 기준을 충족하는 최초 제출

2023년 6월 26일

처음 게시됨 (실제)

2023년 6월 28일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 13일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다